Barclays
MDGL icon

Barclays’s Madrigal Pharmaceuticals MDGL Stock Holding History

Barclays’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-797
Closed -$28K – 6324
2015
Q3 		$28K Sell
797
-106
-12% -$7.65K ﹤0.01% 5311
2015
Q2 		$63K Buy
903
+517
+134% +$43.4K ﹤0.01% 5007
2015
Q1 		$14K Buy
386
+49
+15% +$4.2K ﹤0.01% 6032
2014
Q4 		$24K Sell
337
-277
-45% -$28.6K ﹤0.01% 6214
2014
Q3 		$65K Sell
614
-120
-16% -$16.7K ﹤0.01% 5659
2014
Q2 		$103K Sell
734
-1,077
-59% -$157K ﹤0.01% 5387
2014
Q1 		$254K Sell
1,811
-1,003
-36% -$198K ﹤0.01% 4569
2013
Q4 		$493K Buy
2,814
+2,363
+524% +$433K ﹤0.01% 4108
2013
Q3 		$95K Sell
451
-1,126
-71% -$240K ﹤0.01% 5650
2013
Q2 		$275K Buy
+1,577
New +$411K ﹤0.01% 4865

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's MDGL Position: Q2 2026 in Review

Barclays increased its Madrigal Pharmaceuticals (MDGL) stake by 63% in Q2 2026, buying an estimated $1.08M and bringing the position to 5,489 shares worth $2.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2132.

Barclays first reported a position in MDGL in Q2 2013 and has held it in 53 quarters since. The position peaked at $25.5M in Q4 2022. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Barclays held 5,489 shares of Madrigal Pharmaceuticals worth $2.95M as of Q2 2026.
  • Barclays bought 2,113 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $1.08M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2132 holding.
  • Barclays first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Madrigal Pharmaceuticals position peaked at $25.5M in Q4 2022.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.